Arthur Eichengrün

This article includes a list of general references, but it lacks sufficient corresponding inline citations. Please help to improve this article by introducing more precise citations. (February 2010) (Learn how and when to remove this message)

Arthur Eichengrün
Arthur Eichengrün at Bayer (ca. 1900)
Born	(1867-08-13)13 August 1867 Aachen, Rhine Province, Kingdom of Prussia
Died	23 December 1949(1949-12-23) (aged 82) Bad Wiessee, West Germany
Nationality	German
Alma mater	RWTH Aachen University

Arthur Eichengrün (13 August 1867 – 23 December 1949) was a German Jewish chemist, materials scientist, and inventor. He is known for developing the highly successful anti-gonorrhea drug Protargol, the standard treatment for 50 years until the adoption of antibiotics, and for his pioneering contributions in plastics: co-developing (with Theodore Becker) the first soluble cellulose acetate materials in 1903, called "Cellit", and creating processes for the manufacture of these materials which were influential in the development of injection moulding.^[1] During World War I his relatively non-flammable synthetic cellulose acetate lacquers, marketed under the name "Cellon", were important in the aircraft industry. He contributed to photochemistry by inventing the first process for the production and development of cellulose acetate film, which he patented with Becker.^[2]

Eichengrün claimed to have directed the initial synthesis of aspirin in 1897,^[3] but his claim has been disputed. For many years Bayer credited Felix Hoffmann, Eichengrün's junior, with the invention of aspirin. However, according to some historians the first attribution of the discovery to Hoffmann appears in 1934, and may have reflected anti-Jewish revisionism. Altought Bayer has denied these claims indicating that Hoffman already figured as the inventor in the american patent of aspirin filed in 1899. ^[4]

During World War II, Eichengrün was imprisoned in the Theresienstadt concentration camp.

Arthur Eichengrün was born in Aachen as the son of a Jewish cloth merchant and manufacturer. In 1885, he took up studies in chemistry at the University of Aachen, later moved to Berlin, and finally to Erlangen, where he received a doctoral degree in 1890.

In 1896, he joined Bayer, working in the pharmaceutical laboratory. In 1908, he quit Bayer and founded his own pharmaceutical factory, the Cellon-Werke in Berlin. His company was "Aryanized" by the Nazis in 1938.

In 1943, he was arrested and sentenced to four months in prison for having failed to include the word "Israel" in his name in a letter to a Reich official (Nazi law required Jewish men to be identified as such, as they required Jewish women to identify as "Sarah".). In May 1944, he was arrested again on the same charge and deported to the concentration camp Theresienstadt, where he spent 14 months until the end of World War II in Europe, escaping death.

After the liberation, he returned to Berlin, but moved to Bad Wiessee in Bavaria in 1948, where he died the following year at the age of 82.

Eichengrün has made his name through numerous inventions, such as processes for synthesizing chemical compounds. Aside from Aspirin, Eichengrün held 47 patents. Bayer's official story credits Felix Hoffmann, a young Bayer chemist, with the invention of aspirin in 1897. Impure acetylsalicylic acid (ASA, the active compound of aspirin) had been synthesized already in 1853 by French chemist Charles Frédéric Gerhardt; the 1897 process developed at Bayer was the first to produce pure ASA that could be used for medical purposes.

Due to the rise of the Nazis in Germany, Eichengrün was unable to object when Hoffmann first made the claim that he (Hoffman) invented aspirin, in the footnote of a 1934 German Encyclopedia. Hoffmann's claim was once widely accepted, but many historians now consider it to be discredited. Eichengrün first claimed to have invented aspirin in a 1944 letter from Theresienstadt concentration camp, addressed to IG Farben (of which Bayer was a part), where he cited his many contributions to the company (which was highly influential in the concentration camps), including the invention of aspirin, as reasons for why he should be released.

Five years later, Arthur Eichengrün published a paper in Pharmazie in 1949, where he explained that he had instructed Hoffmann to synthesise acetylsalicylic acid and that the latter had done so without knowing the purpose of the work. The paper elucidated how he planned and directed the synthesis of aspirin along with the synthesis of several related compounds, describing these events in detail. He also claimed to be responsible for aspirin's initial surreptitious clinical testing.^[3] Finally, he explained that Hoffmann's role was restricted to the initial lab synthesis using his (Eichengrün's) process and nothing more.^[5]

Eichengrün's account was largely ignored by historians and chemists until 1999, when Walter Sneader of the Department of Pharmaceutical Sciences at the University of Strathclyde in Glasgow re-examined the case and came to the conclusion that indeed Eichengrün's account was convincing and correct and that Eichengrün deserved credit for the invention of aspirin.^[4] Bayer denied this in a press release, asserting that the invention of aspirin was due to Hoffmann.^[6]

Evidence supporting Eichengrün's claims to the invention

Walter Sneader based his claims that Eichengrün both invented the process for synthesizing aspirin and oversaw its clinical testing on old and newly released archived materials, including letters, patents, and lab work. He found that Hoffmann was not credited with inventing the process for synthesizing Aspirin in any documents prior to 1934, 37 years after its initial synthesis. Further he found reason to doubt the footnote's credibility, not just for being published during the "Aryanization" period of Nazi Germany, but for its inaccurate claims about the testing of salicylic acid derivates other than acetyl ester. The vague reference did not specify which derivatives were tested, but claimed they had been discovered earlier but had been synthesized for "other purposes".^[7] No indication was given of what the others were, but in 1899 Heinrich Dreser, head of the experimental pharmacology laboratory at Elberfeld, named them in a publication as propionyl, butyryl, valeryl, and benzoyl salicylic acids.^[8] He further alluded to these derivatives in 1907^[9] and again in 1918.^[10] However, the assertion that these salicylic acid derivates had been synthesized for non-therapeutic reasons is demonstrably false. Hoffmann's colleague Otto Bonhoeffer (who also worked under Eichengrün) had been awarded a US and UK patent in 1900 for several of these compounds.^[11][12] The patents indicate that the derivatives were prepared for the exact purpose of finding a salicylic acid derivative with therapeutic value. Sneader concluded that because of this error the 1934 footnote is unreliable.

However Bayer dismissed Sneader claims asserting Hoffman invention of the Aspirin. According to Bayer, Hoffmann and Eichengrün were colleagues of equal standing at Bayer, not in a hierarchical relationship. This undermines Sneader's claim that Hoffmann worked under Eichengrün's direction. Numerous documents, including Hoffmann's laboratory journal entry from August 10, 1897, explicitly record his synthesis of ASA, providing clear evidence of his role in this pivotal discovery. Additionally, Hoffmann is recognized as the inventor in the American patent for ASA, filed in 1899. Notably, Eichengrün never contested this acknowledgment during his tenure at Bayer, further solidifying Hoffmann’s claim to the invention. Eichengrün’s assertions lack timely credibility, as he did not claim credit for the synthesis until 1949—more than 50 years after Hoffmann's documented work. This delay raises questions about the validity of his late claims to authorship. Furthermore, the narrative suggesting that Eichengrün's Jewish background led to the suppression of his contributions lacks substantive evidence. Throughout his career, Eichengrün was a successful inventor with numerous patents and never demanded recognition for ASA during his time at Bayer.^[13]

In 1897, protargol, a silver salt of a protein mixture, developed by Eichengrün at Bayer, was introduced as a new drug against gonorrhea. Protargol stayed in use until sulfa drugs and then antibiotics became available in the 1940s.^[14]

In 1903, Eichengrün co-developed the first soluble form of cellulose acetate with Theodore Becker. He developed processes for the manufacture of cellulose acetate materials and devoted the rest of his life to the technical and economic development of plastics, lacquers, enamels, and artificial fibers based on cellulose acetate. During World War I his relatively non-inflammable synthetic cellulose acetate lacquers were important in the aircraft industry. He also pioneered the influential technique of injection moulding. In 1904, he created and patented the first safety film with Becker, (cellulose diacetate) from a process they devised in 1901 for the direct acetylation of cellulose at a low temperature to prevent its degradation, which permitted the degree of acetylation to be controlled, thereby avoiding total conversion to its triacetate. Cellit was a stable, non-brittle cellulose acetate polymer that could be dissolved in acetone for further processing. It was used to manufacture cellulose diacetate cinematographic film, which Eastman Kodak and the Pathé Frères began to use in 1909. Cellulose acetate film became the standard in the 1950s, preferred over the highly flammable and unstable film stock produced from Nitrocellulose.

• Arthur Eichengrün in the Complete Dictionary of Scientific Biography
• Sneader's paper crediting Eichengrün with the invention of aspirin in the British Medical Journal.
• Bayer's press release denying this at the Wayback Machine (archived September 28, 2007) (in German)
• Wer hat es erfunden? (Who invented it?) (in German)
• Gratzer, Walter (2002). "Truth Stranger than Fiction". Eurekas and Euphorias; The Oxford Book of Scientific Anectodes. New York: Oxford University Press. pp. 209-210. ISBN 978-0-19-280403-7. Retrieved December 12, 2018 – via Internet Archive.